Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...

Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...

Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...

Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...